A Phase 3 interventional study of Donepezil Hydrochloride in Dementia, Vascular, sponsored by Eisai Inc.. Completed at 5 sites in United States. Open to participants aged 41 Years and older. Per ClinicalTrials.gov, last updated 2011-04-01.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Dementia, Vascular with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Dementia, Vascular · United States.
Among the 65 studies in Dementia, Vascular with a site in United States, this one is the 5th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2003, is one of 5 in phase 3, and was the 3rd registered.
183 studies on the registry are indexed under Dementia, Vascular; 42 are open to participants now.
Browse Dementia, Vascular studies →16 of the 65 studies in Dementia, Vascular with a site in United States are open now. Recruiting first, the newest first:
Hopeful Aging · Sites in United States
Ages 18–103 · Healthy volunteers
Hopeful Aging · Sites in United States
Ages 65+
Herrick Medical LLC · Sites in United States
Ages 50–100
Center for Clinical Studies, Texas · Sites in United States
Ages 18+ · Healthy volunteers
Jasmohan Bajaj · Sites in United States
Ages 65+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Dementia, Vascular studies recruiting now, 25 (71%) set no upper age limit and 2 (6%) stop at 75 or younger; 4 take children under 18; 13 take healthy volunteers.
This study: 41 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 974 is above the median of 123 across 116 interventional studies indexed under Dementia, Vascular.
Median enrollment 100 across the 47 interventional studies, 375 across the 17 observational. Of the 41 that completed or were terminated, 20 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 3 studies filed under Dementia, Vascular — fewer than ten, so there is no comparison to draw.
10 of the studies in Dementia, Vascular with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT06034509Walter Reed National Military Medical CenterCognitive and Vascular Functioning Following TBI | 2027-01 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05704309Marinella TemprosaThe Diabetes Prevention Program Outcomes Study AD/ADRD Project | 2027-01-31 |
| NCT06079216Hopeful AgingMaking Connections Thru Music | 2027-04-29 |
Add all 10 to your calendar (.ics) → With an account.
Among the 65 studies in Dementia, Vascular with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Twenty-four week, prospective, randomized, double-blind, placebo-controlled, parallel-group study.
Inclusion Criteria:
-- Patients with prosthetic heart valves, who require full anticoagulation, should have a stable (>= 3 months) INR in the range of 2.5-3.5.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Safety: physical examinations, ECG and clinical laboratory tests. Efficacy: Vascular-Alzheimer's Disease Assessment Scale-Cognitive subscale (V-ADAS-cog) and the Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-Plus).
Time frame: Parameters will be measured prior to, during and at the end of the study.
The record gives a start of Mar 2003, a primary completion of Aug 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil